TI
LOGC

Trexquant Investment’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Trexquant Investment’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-46,229
Closed -$205K – 1614
2021
Q2 		$205K Buy
46,229
+30,288
+190% +$154K 0.02% 903
2021
Q1 		$116K Buy
+15,941
New +$131K 0.01% 1042

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Trexquant Investment's LOGC Position: Q3 2021 in Review

Trexquant Investment sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q3 2021, closing a stake of 46,229 shares — an estimated $205K sold.

Trexquant Investment first reported a position in LOGC in Q1 2021 and held it in 2 quarters. The position peaked at $205K in Q2 2021. 57 funds tracked by Wall St. Rank hold LOGC as of Q3 2021.

  • Trexquant Investment reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Trexquant Investment sold 46,229 LogicBio Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $205K.
  • Trexquant Investment first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Trexquant Investment's LogicBio Therapeutics, Inc. Common Stock position peaked at $205K in Q2 2021.
  • 57 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Trexquant Investment's 13F filing for Q3 2021, filed 12 Nov 2021.